Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML

NCT03727750 · clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
51
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Pfizer